Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Laura TorrensCarla MontironiMarc PuigvehíAgavni MesropianJack LesliePhilipp K HaberMiho MaedaUgne BalaseviciuteCatherine E WilloughbyJordi Abril-FornagueraMarta Piqué-GiliMiguel Torres-MartinJudit PeixDaniel GehErik Ramon-GilBehnam SaberiScott L FriedmanDerek A MannDaniela SiaJosep M LlovetPublished in: Hepatology (Baltimore, Md.) (2021)
Lenvatinib plus anti-PD1 exerted unique immunomodulatory effects through activation of immune pathways, reduction of Treg cell infiltrate, and inhibition of TGFß signaling. A gene signature enabled the identification of ~20% of human HCCs that, although nonresponding to single agents, could benefit from the proposed combination.